{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=39",
    "query": {
      "condition": "Phase 1",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 18615,
    "total_pages": 1862,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T13:43:00.173Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05081609",
      "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Locally Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Platinum-resistant Ovarian Cancer",
        "Post Anti-PD-1 Melanoma",
        "2L+ Cervical Cancer",
        "Neoadjuvant Melanoma",
        "Neoadjuvant Non-Small Cell Lung Cancer",
        "Post Anti-PD-(L)1 Non-Small Cell Lung Cancer",
        "Post Anti-PD-(L)1 Small Cell Lung Cancer",
        "Third Line or Later (3L+) HER2+ Breast Cancer",
        "Second or Third Line (2L/3L) Cervical Cancer",
        "Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)"
      ],
      "interventions": [
        {
          "name": "TransCon IL-2 β/γ",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy drug",
          "type": "DRUG"
        },
        {
          "name": "TransCon TLR7/8 Agonist",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab emtansine (T-DM1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ascendis Pharma Oncology Division A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2022-01-11",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-29T13:43:00.173Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05081609"
    },
    {
      "nct_id": "NCT05585632",
      "title": "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2",
        "Influenza",
        "RSV"
      ],
      "interventions": [
        {
          "name": "mRNA-1010",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.214",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1045",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1230",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 392,
      "start_date": "2022-10-14",
      "completion_date": "2024-02-28",
      "has_results": false,
      "last_update_posted_date": "2024-03-08",
      "last_synced_at": "2026-10-29T13:43:00.173Z",
      "location_count": 14,
      "location_summary": "DeLand, Florida • Hollywood, Florida • St. Petersburg, Florida + 11 more",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05585632"
    },
    {
      "nct_id": "NCT00002587",
      "title": "Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "1994-09",
      "completion_date": "2000-12",
      "has_results": false,
      "last_update_posted_date": "2013-06-03",
      "last_synced_at": "2026-10-29T13:43:00.173Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002587"
    },
    {
      "nct_id": "NCT05721287",
      "title": "A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain",
        "Acute Pain"
      ],
      "interventions": [
        {
          "name": "SBS-1000",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sparian Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 48,
      "start_date": "2023-01-30",
      "completion_date": "2023-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-10-29T13:43:00.173Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05721287"
    },
    {
      "nct_id": "NCT00253721",
      "title": "Melphalan With BBBD in Treating Patients With Brain Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Lymphoma",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "Melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 21,
      "start_date": "1998-05",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-10-29T13:43:00.173Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00253721"
    },
    {
      "nct_id": "NCT03510104",
      "title": "Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer",
        "Neoplasms",
        "Neoplasm Metastasis",
        "Neoplastic Processes",
        "Pathologic Processes"
      ],
      "interventions": [
        {
          "name": "MRX-2843",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Meryx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2018-05-22",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-10-29T13:43:00.173Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03510104"
    },
    {
      "nct_id": "NCT00248404",
      "title": "NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Tumors"
      ],
      "interventions": [
        {
          "name": "NB1011",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kiadis Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2005-09",
      "completion_date": "2007-12-12",
      "has_results": false,
      "last_update_posted_date": "2022-05-16",
      "last_synced_at": "2026-10-29T13:43:00.173Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00248404"
    },
    {
      "nct_id": "NCT04999384",
      "title": "First in Human, Dose Escalation Study of AN4005",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Lymphoma"
      ],
      "interventions": [
        {
          "name": "AN4005-dose level 0",
          "type": "DRUG"
        },
        {
          "name": "AN4005-dose level 1",
          "type": "DRUG"
        },
        {
          "name": "AN4005-dose level 2",
          "type": "DRUG"
        },
        {
          "name": "AN4005-dose level 3",
          "type": "DRUG"
        },
        {
          "name": "AN4005-dose level 4",
          "type": "DRUG"
        },
        {
          "name": "AN4005-food effect",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adlai Nortye Biopharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2021-09-27",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-10-29T13:43:00.173Z",
      "location_count": 4,
      "location_summary": "Hackensack, New Jersey • The Bronx, New York • Greenville, South Carolina + 1 more",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04999384"
    },
    {
      "nct_id": "NCT07717814",
      "title": "A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "AMG 133 (frozen liquid)",
          "type": "DRUG"
        },
        {
          "name": "AMG 133 (liquid)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 154,
      "start_date": "2024-11-26",
      "completion_date": "2025-06-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-10-29T13:43:00.173Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07717814"
    },
    {
      "nct_id": "NCT02521714",
      "title": "Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 28,
      "start_date": "2015-08-14",
      "completion_date": "2015-09-23",
      "has_results": false,
      "last_update_posted_date": "2019-11-08",
      "last_synced_at": "2026-10-29T13:43:00.173Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02521714"
    }
  ]
}